Immunoxel (Dzherelo) vs Imunofan — Peptide Comparison

Immunoxel (Dzherelo) vs Imunofan — Peptide Comparison Immunoxel (Dzherelo) vs Imunofan — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Immunoxel (Dzherelo) 25–50 drops Imunofan 50–100 mcg Frequency Multiple times daily Once daily Administration Oral (liquid drops) Subcutaneous injection Cycle Length 8-12 weeks Onset Speed Moderate (1-2 weeks) Rapid (hours to days) Evidence Level Moderate human trials (Phase 1-2) Limited human trials Efficacy TB Treatment Enhancement Immune Restoration Infection Prevention Immune Healing & Recovery Anti-Aging Technical Data Molecular Formula N/A — multi-component herbal phytoconcentrate Molecular Weight N/A — complex botanical mixture of multiple plant compounds Half-Life Not precisely characterized; immunomodulatory effects develop over days to weeks of consistent dosing Bioavailability Good oral and sublingual bioavailability; sublingual lozenges shown equivalent to twice-daily oral liquid CAS Number Proprietary combination C36H61N13O10 836.0 g/mol Approximately 2-4 hours (intranasal administration) ~90-95% (subcutaneous injection) Not assigned (Russian pharmacopeia compound) Protocols standard 30-50 drops (approx. 1-2 mL) of liquid concentrate Twice daily 1-6 months alongside anti-TB therapy Dose used as adjunct immunotherapy with standard anti-tuberculosis treatment in clinical trials [3]; meta-analysis supports adjunctive benefit [1]. 1 lozenge/pastille (equivalent to the twice-daily oral liquid dose) Sublingual formulation clinically validated as equivalent to twice-daily oral liquid in TB patients [2]. 45 mcg per dose Once daily or every other day Course of 5-15 injections (about 10-30 days) Standard injectable dose per the Russian pharmacopeia product label; the single subcutaneous dose is 45 mcg with a maximum daily dose of 45 mcg. Given in courses depending on the indication [1][5]. Same 45 mcg single dose can be given intramuscularly; identical course structure to the subcutaneous route [1][5]. 50 mcg per dose (one spray in each nostril) Once to twice daily 8-15 days per course Intranasal spray delivers 50 mcg per dose; one dose into each nasal passage once daily for 8-10 days, or twice daily for 10-15 days for certain indications [5]. Applications Tuberculosis Adjunct Treatment Immunoxel's strongest evidence is as an add-on to standard TB drugs. A meta-analysis of 6 clinical trials found patients receiving Immunoxel were 3.19 times more likely to become sputum-negative compared to TB drugs alone. In one study, 84.1% of patients converted within 1 month versus only 19% on placebo. HIV/TB Coinfection Immune Support For patients battling both HIV and TB simultaneously, Immunoxel offers remarkable immune benefits. Clinical trials showed CD4+ T-cell counts increased by 71.2% in just 2 months, viral load decreased significantly, and opportunistic infections dropped from 12 episodes to just 3 compared to standard therapy alone. Drug-Resistant Tuberculosis Support Immunoxel has been studied in multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) patients where standard treatments often struggle. Its immune-boosting effects help the body fight TB even when the bacteria resist front-line drugs. Cancer Adjuvant Therapy Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness. Chronic Viral Hepatitis With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery. Chronic Infections with Immunodepression Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months. Oxidative Stress Reduction The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance. Safety Profile Common Well-tolerated in most patients Mild gastrointestinal discomfort Uncommon Temporary taste changes Mild allergic skin reactions Mild headache Serious Potential herb-drug interactions Injection site reaction Transient headache Nasal irritation (intranasal form) Transient mild fever Mild fatigue Gastrointestinal discomfort (suppository form) Allergic reaction Anaphylactic reaction / Severe hypersensitivity Research Status FDA Status Research compound Safety Overview Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature. Contraindications xKnown hypersensitivity to any of the plant ingredients in the formulation xPregnancy and breastfeeding (insufficient safety data) xSevere liver disease (contains alcohol-based extract) xUse as sole therapy for TB or HIV (must be combined with standard treatment) Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses. xKnown hypersensitivity to imunofan or excipients xPregnancy complicated by Rh-conflict (contraindicated) xChildren under 2 years of age xSevere allergic conditions in acute exacerbation Decision Guide Choose Immunoxel (Dzherelo) if... Adjunct immunotherapy alongside tuberculosis treatment Immune restoration in HIV/TB coinfected patients Reducing opportunistic infection rates Supporting overall immune function during infectious disease treatment Choose Imunofan if... Immune system restoration and modulation Adjunctive therapy during chemotherapy and radiation Support during chronic hepatitis treatment Reducing oxidative stress and free radical damage